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Abstract 
Over the past decades, it has become clear that the most efficient way to prevent status 
epilepticus is to stop the seizure as fast as possible, and early treatment of prolonged 
convulsive seizures has become an integral part of the overall treatment strategy in 
epilepsy. Benzodiazepines are the first choice drugs to be used as emergency 
medication. This treatment in the early phases of a seizure often implies a ‘pre-medical’ 
setting before intervention of medically trained persons. In this paper, we propose 
“good practice points” for first line management of prolonged convulsive seizures in 
children and adults in a ‘pre-medical’ setting. 
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Introduction 
In recent years, early treatment of prolonged convulsive seizures has become an 
integral part of the overall treatment strategy in epilepsy [1]. It is clear that the most 
efficient way to prevent status epilepticus is to stop the ongoing seizure as fast as 
possible, ideally within the first minutes. Chin et al. demonstrated that one of the major 
predictors for long lasting seizures and status epilepticus was inadequate or lack of use 
of benzodiazepines (BZP) in the early stages of the seizure [2]. It is recognized that early 
management should imply administration of treatment before the intervention of a 
medically trained emergency team or before arrival at the emergency department of 
the hospital. This ‘pre-hospital’ intervention in the community is considered the first and 
perhaps the most important phase in the treatment of an acute prolonged convulsive 
seizure, followed by a second phase with intravenous (IV) anti-epileptic drug 
administration, and eventually a third intensive care phase with anesthetic drugs if 
necessary [3]. In this paper we propose “good practice points” for the treatment of 
prolonged convulsive seizures in children and adults. The treatment of non-convulsive 
seizures and status epilepticus is not within the scope of this paper. 
 
Methodology 
A group of Belgian epilepsy experts, adult and pediatric neurologists, and an 
emergency/intensive care pediatrician, came together to review and discuss guidelines 
for the first line treatment of prolonged or repetitive convulsive seizures in children and 
adults in Belgium. Prior to this expert meeting, the scientific literature (Pubmed) was 
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searched for international treatment guidelines for seizures, and relevant controlled 
clinical trials. The discussion was based primarily on international guidelines published 
by the UK National Institute for Clinical Excellence (NICE, 2013) and the European 
Federation of Neurological Societies (EFNS, updated in 2011), and on the personal 
experience of the experts. The information in these published guidelines combined with 
the experts experience, was translated into good practice points for the use of 
emergency medication in the Belgian situation. All the members of the expert group 
read the first draft of the good practice points and discussed changes to reach an 
informative consensus. 
  
Prolonged convulsive seizures: what, when and whom to treat? 
Longer lasting seizures can cause direct damage to the brain by inducing brain edema 
and ischemia [4], but they also cause systemic effects such as rhabdomyolysis, 
metabolic dysregulation and acute disturbance of autonomic functions, including gastric 
paresis and cardiac arrhythmia. An almost linear relationship exists between the 
duration of the seizure and the risk for secondary brain damage [4]. It is generally 
accepted that convulsive seizures are more harmful than non-convulsive seizures. 
Clinical data indicate that spontaneous cessation of generalized convulsive seizures is 
unlikely after 5-10 minutes [5, 6]. The risk of a long-lasting seizure or status epilepticus 
(with considerable morbidity and mortality) is very significant whenever a convulsive 
seizure lasts for more than 5-10 minutes [6, 7]. Recent studies have elucidated a 
mechanism possibly underlying this phenomenon. It was shown in small animal models 
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that during a seizure the postsynaptic inhibitory GABA-A receptors get internalized in 
the cell. At the same time, more excitatory glutamate receptors appear on the cell 
surface making the cell more excitable [8, 9]. These dynamic processes occurring during 
a seizure are important to understand treatment options and possible treatment 
failures in prolonged seizures. However, this principle remains to be proven in clinical 
practice in humans. The window of opportunity to give the classic GABA-ergic drugs (e.g. 
benzodiazepines (BZP)) is probably in the early phase of a seizure, being the first 5 to 10 
minutes. Therefore, it is proposed to give a first dose of emergency medication when 
the convulsive seizure does not stop after 5 minutes. This implies that most often a non-
medically trained person has to administer the emergency medication in the community 
(e.g. at home, at work, at school or in a sports club). Therefore, parents, grandparents, 
teachers, caregivers, partners and other people who are in close contact with the 
patient, should be educated. 
These good practice points should always be considered in case of convulsive seizures in 
patients known with epilepsy, and with a history of prolonged (lasting more than 5 
minutes) or repetitive (3 or more in an hour) convulsive seizures. It was shown by 
Shinnar et al. [6, 10] that in children the duration of a subsequent seizure correlates 
very well with the duration of the first seizure, making it possible to define a high risk 
group for whom it is advisable to prescribe acute treatment. We do not usually 
recommend prescription of emergency medication to any patient who experienced a 
short (less than 5 minutes) convulsive seizure of any type. For instance, in benign 
rolandic epilepsy, childhood absence epilepsy or juvenile myoclonic epilepsy, the risk for 
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prolonged convulsive seizures is known to be low. Therefore, an individualized care plan 
should be made for every patient, based on the epilepsy syndrome diagnosis, the type 
or duration of the usual seizure, and the experience of the treating physician. 
Emergency treatment could also be considered for prolonged febrile seizures. Other 
target populations are non-compliant patients and the group of patients with a history 
of prolonged seizures in whom one tapers anti-epileptic drugs after a long period of 
seizure freedom. During tapering and in the first months after stopping of the drugs, 
there is a risk for recurrence of seizures.  
 
General management of prolonged convulsive seizures 
When a person experiences a convulsive seizure that lasts longer than 5 minutes, 
airway/breathing/circulation (ABC) management comes at the first place. Lay care givers 
should check if the mouth of the patient is empty, and position the head and body of 
the patient so to enable a free airway. Breathing should be assessed by feeling with the 
cheek and looking for chest expansion. If breathing is absent, or only gasping is present, 
cardiopulmonary resuscitation should be started. In any case of prolonged convulsive 
seizures emergency medical services should be alerted (European emergency number 
112). Safety of both the patient and caregiver themselves should be guaranteed: objects 
that could hurt the patient should be removed, restraining garments should be 
loosened, the environment should be safe,… 
 
Benzodiazepines 
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First line medication to be administered in the community should be effective (fast 
action), safe, easy and socially acceptable to administer, and stable for conservation 
during a long period. There is consensus about the use of benzodiazepines (BZP) to treat 
prolonged convulsive seizures. Their working mechanism is well known. BZP activate the 
binding of GABA to the post-synaptic inhibitory ionotropic GABA-A receptor, thereby 
opening a chloride channel and hyperpolarizing the postsynaptic neuron, leading to a 
decreased neuronal excitability [11, 12]. BZP typically reach the brain within minutes. 
Studies in rodents showed that the ictal discharges disappear within 5 to 10 minutes, 
together with the onset of post-ictal slow waves on the EEG. However, there are subtle 
but perhaps clinically important differences between BZP. The onset of effect is faster 
for midazolam (MDZ) than for lorazepam (LZP) and diazepam (DZP), but the duration of 
the effect is much longer for LZP than for MDZ and DZP. This may also explain why the 
hangover effects like drowsiness, sleepiness or abnormal behavior may last longer for 
LZP than for MDZ. The risk of respiratory depression is a real issue but should not be 
over-estimated, as was shown in several studies [2, 13, 14]. The seizure itself may cause 
respiratory depression. This is supported by the observation that respiratory depression 
occurs more frequently with placebo [13]. Furthermore, the BZP-related risk of 
respiratory depression is related to individual sensitivity and dosage. In clinical practice, 
a single correct dosage of BZP poses only a very minimal risk for respiratory depression 
[2, 15].  
Early treatment implies that administration should be kept simple and easy (Table 1 and 
flowchart). On the spot calculation of the dosage and complex handling procedures of 
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the product should be avoided. Intrabuccal (IB) LZP (0.05-0.1 mg/kg or 0-2 years : 1 mg 
and >2 years : 2.5 mg) and IB MDZ (0.2-0.5 mg/kg, maximum 10 mg in one dosis) are the 
medications of choice [16, 17] for first line treatment of prolonged or repetitive 
convulsive seizures. Intramuscular (IM) MDZ (0.1-0.2 mg/kg, maximum 10 mg) is 
another safe and effective option [14], particularly in patients who have hypersalivation 
or spitting during seizures, leading to inadequate dosing. However, this can only be 
administered by a medically trained person. Intranasal (IN) MDZ can also be given (0.2-
0.5 mg/kg, maximum 10 mg). Although effective, intrarectal (IR) administration of DZP 
(0.5 mg/kg, maximum 10 mg) cannot be advocated anymore, since it is not only socially 
unacceptable, but it is also more difficult to administer in a seizing person and there is a 
high risk of spillage of the product. However, in certain situations, e.g. in babies or 
infants, in cases where no IV access can be obtained, when MDZ or LZP are not 
available, IR DZP might still be considered.  
Most experts use an immediate release of IB LZP (Temesta Expidet® 1 or 2.5 mg) that 
can be given sublingually. It very rapidly diffuses to the blood through the oral mucosa. 
Evidence-based data for this formulation are lacking however. A prescription for MDZ 
should be handled with care, as multiple dilutions exist on the Belgian market: 
Dormicum®, Midazolam B Braun®, Midazolam Mylan®, each in 15 mg/3 ml, 5 mg/5 ml or 
50 mg/10 ml. For evident reasons of volume to be given (IB/IN/IM) the first dilution (15 
mg/3 ml) should be used. A ready-to-use IB MDZ oromucosal solution (Buccolam® 2.5 
mg/0.5 ml, 5 mg/0.5 ml, 7.5 mg/0.5 ml and 10 mg/0.5 ml) is available in several 
European countries, and this product is supposed to be launched on the Belgian market.  
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The first dose of BZP can be given by the parents, grandparents, partners or educated 
caregivers in the community (Table 1 and flowchart). If needed, a second dose should be 
given by medically trained people, being the general practitioner, a doctor arriving with 
the emergency team, or a doctor in the emergency room. This second dosage of BZP, 
preferentially IV LZP (0.05-0.1 mg/kg) or DZP (0.1-0.3 mg/kg), should be administered 
with more intensive monitoring (Table 2 and flowchart). If IV access can not be 
obtained, another dose of IB/IN/IM MDZ, IB LZP or IR DZP can be given [14]. See Table 1 
and Table 2 for preparations, formulations and dosages.  
 
Recommendations for treatment 
 In a patient with a well-established epilepsy diagnosis and with a history of 
prolonged (lasting 5 minutes or longer) convulsive seizures, including repetitive 
seizures (3 or more in an hour), it is good practice to prescribe and explain 
emergency BZP treatment. Parents, grandparents, partners and caregivers 
should be educated about the use of these emergency drugs. 
 Whenever a patient with known epilepsy experiences a convulsive seizure lasting 
longer than 5 minutes, BZP should be given to avoid a pending status epilepticus.  
 Care should be taken to secure the person’s airway and assess respiratory and 
cardiac function. 
 IB MDZ and IB LZP are recommended as first line treatment for children and 
adults with prolonged or repetitive seizures in the community. IR administration 
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is not preferred anymore, but can be used as an alternative. Another alternative 
is IN or IM MDZ. 
 After a first BZP dosage, a medical professional should decide on the next 
treatment step when the seizure did not stop within 10 minutes. This should be 
a second dosage of BZP, preferentially IV LZP or DZP.  
 If 2 dosages of BZP fail, second line treatment in a hospital setting with intensive 
monitoring of vital functions is mandatory. In most protocols, IV phenytoin, 
levetiracetam or valproate, followed by general anesthesia with continuous 
MDZ, thiopental or propofol are preferred [18]. In some guidelines, IV 
phenobarbital is still recommended, but its place in the treatment algorithm has 
become controversially. 
 
Conclusions 
In this consensus paper, we emphasized the importance of early treatment of acute 
prolonged or repetitive convulsive seizures. BZP are recommended as first choice 
emergency treatment to be used in the community by non-medically trained persons. 
The risk for side effects (especially respiratory depression) is much smaller than the 
potential benefit of preventing status epilepticus. In children and adults, IB MDZ or IB 
LZP are recommended as first line treatment. The second dose of BZP should 
preferentially be IV LZP or DZP administered by a medically trained person. 
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Table 1: Benzodiazepine formulations and dosing proposal for first administration (IB or 
IN) in prolonged and repetitive convulsive seizures in children and adults. 
 
Product Route Children Adults 
diazepam (DZP) 
(Valium® 10 mg/2 ml) 
IR 0.5 mg/kg (max. 10 mg) 
< 2 years: 2.5 mg 
2-5 years: 5 mg 
>5 years: 10 mg 
10 mg 
lorazepam (LZP) 
(Temesta Expidet® 1 mg, 2.5 mg) 
IB 
 
 
0.05-0.1 mg/kg (max. 5 mg) 
0-2 years: 1 mg 
>2 years: 2.5 mg 
2.5 mg 
 
 
midazolam (MDZ) 
(Dormicum® 15 mg/3 ml, 
Midazolam B. Braun® 15 mg/3ml, 
Midazolam Mylan® 15 mg/3 ml, 
Buccolam® 2.5 mg/0.5 ml, 5 
mg/0.5 ml, 7.5 mg/0.5 ml, 10 
mg/0.5 ml) 
IB/IN 
 
 
 
0.2-0.5 mg/kg (max. 10 mg) 
3 months-1 year: 2.5 mg 
1-5 years: 5 mg 
5-10 years: 7.5 mg 
10-18 years: 10 mg 
10 mg 
 
DZP: diazepam, LZP: lorazepam, MDZ: midazolam, IB: intrabuccal, IN: intranasal, IR: 
intrarectal, kg: kilogram, max: maximum, mg: milligram 
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Table 2: Benzodiazepine formulations and dosing proposal for second administration 
(IM or IV) in prolonged and repetitive convulsive seizures in children and adults. 
 
Product Route Children Adults 
diazepam (DZP) 
(Valium® 10 mg/2 ml) 
IV 0.1-0.3 mg/kg (max. 5 mg) 10 mg 
lorazepam (LZP) 
(Temesta® 4 mg/ml, 
Tavor® 2 mg/ml) 
IV 
 
0.05-0.1 mg/kg (max. 2 mg) 5-10 mg 
midazolam (MDZ) 
(Dormicum® 15 mg/3 
ml, Midazolam B 
Braun® 15 mg/3 ml, 
Midazolam Mylan® 15 
mg/3 ml) 
IM 
 
 
IV 
0.1-0.2 mg/kg (max. 10 mg) 
13-40 kg: 5 mg 
>40 kg: 10 mg 
0.1-0.3 mg/kg (max. 10 mg) 
10 mg 
 
DZP: diazepam, LZP: lorazepam, MDZ: midazolam, IM: intramuscular, IV: intravenous, 
kg: kilogram, max: maximum, mg: milligram, min: minute 
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Flowchart: Management of prolonged convulsive seizures. 
 
DZP: diazepam, LZP: lorazepam, MDZ: midazolam, IB: intrabuccal, IM: intramuscular, IN: 
intranasal, IR: intrarectal, IV: intravenous 
